Cargando…

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

OBJECTIVE: To assess whether it is feasible to establish specific cut-off values able to discriminate ‘physiological’ or ‘pathological’ brain volume rates in patients with multiple sclerosis (MS). METHODS: The study was based on the analysis of longitudinal MRI data sets of patients with MS (n=206,...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Stefano, Nicola, Stromillo, Maria Laura, Giorgio, Antonio, Bartolozzi, Maria Letizia, Battaglini, Marco, Baldini, Mariella, Portaccio, Emilio, Amato, Maria Pia, Sormani, Maria Pia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717444/ https://www.ncbi.nlm.nih.gov/pubmed/25904813 http://dx.doi.org/10.1136/jnnp-2014-309903

Ejemplares similares

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Impact of the COVID‐19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy
por: Colais, Paola, et al.
Publicado: (2021)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis
por: Solaro, Claudio, et al.
Publicado: (2022)

Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2022)

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
por: López-Gómez, Carlos, et al.
Publicado: (2016)

A real‐world study of alemtuzumab in a cohort of Italian patients
por: Russo, Cinzia Valeria, et al.
Publicado: (2021)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kcv0i1j4btfsnvgc67ta4c7j6i